Skip to content
problem genome

One of 592 unsolved problems in the Problem Genome, a collection written up for student design and engineering teams.

health · digital

it helped, but the old aids won

In a UK home trial a wearable electronic magnifier improved older adults' self-reported visual ability, but no more than 2 of 34 preferred it for any task, and the number willing to buy it fell from 25 of 34 to 8

Source: Miller et al., “The Usefulness of a Wearable Electronic Vision Enhancement…” Open ↗source: primaryLast updated: 2026-11-17

Problem statement

People with age-related macular degeneration (AMD) lose central vision and get by with a drawer of aids: hand magnifiers, stand magnifiers, video magnifiers, phones and tablets. Wearable electronic vision enhancement systems (wEVES) are headsets with a camera and a screen in front of each eye that can zoom, brighten and add contrast at any distance, and they are marketed for AMD. In a randomised crossover trial in older people with AMD, recruiting from a low vision service in Birmingham, UK, and local support groups, 34 adults (mean age 80) used a spectacle-style headset alongside their usual aids at home for about 6 weeks, and their usual aids alone for about 6 weeks. Their self-reported visual ability improved with the headset, and they tried it for many tasks, including distance tasks such as TV and faces, for which many had no aid at all. But their vision-related quality of life did not change. Asked afterwards which aid they preferred for each task, no more than 2 of the 34 chose the headset for any single task, and the authors report it was not the preferred device across people for any task or across tasks for any person. That held even for recognising faces, where most who tried it rated it better than their alternatives. In interviews afterwards, users named problems with the image (its quality, the screen size) and, separately, practical ones: it took too long to find, charge, switch on and set up for a quick look; it was wired to a separate phone-sized controller; it could not correct their distance spectacle prescription; it got warm, and some found even its 78 g heavy. The unsolved problem is a wearable magnifier that is quicker and less bother to reach for than a £50 hand magnifier for the short "spot" tasks older users actually do, so that the visual gain it measurably gives is used.

Why this matters

AMD caused blindness for an estimated 1.85 million people and moderate to severe vision impairment for 6.23 million in 2020, the trial paper reports, and total prevalence is estimated to reach 288 million by 2040. Treatment options continue to emerge, but many people are left needing rehabilitation and aids. The tested headset retailed at £3999 (a UK retailer's page now marks that model "Discontinued", replaced by the EYE7). Interest was high at first: 81% (34 of 42) of people shown the device in clinic chose to take it home, and 25 of 34 said at drop-off that they would buy one. By collection, 8 of 34 would. Asked how much they would pay if money were no problem, the median fell from £300 to £0, so the fall reflects how much they valued it, not what they could afford. The authors warn that a short demonstration in a clinic or shop, where the device looks impressive, tells less than a home trial about whether an older person will find it useful. That matters for anyone prescribing or buying one. It also matters for a device type whose earlier studies mostly measured eyesight gains against a baseline rather than against the aids users already had.

What’s been tried and why it hasn’t worked

(1) The headset itself (UK trial, 2025). A patient group chose the Eyedaptic Eye5 from the wEVES on sale in the UK: a non-enclosed, glasses-style headset tethered by a wire to controls on a repurposed Android phone. Each participant first had a full low vision assessment, with spectacles and optical aids brought up to date, then about 2 hours of face-to-face training (mean 123 minutes; 30 of 34 needed two sessions and 4 needed a third). Participants were asked not to use it while moving, because the fall risk was unknown and makers of similar devices advise against it. Results: visual ability on the VA-VFQ48 questionnaire improved (mean logit difference −0.26; 95% CI −0.48 to −0.04; P = 0.02); two quality-of-life measures did not change (VCM-1 P = 0.59; VisQoL P = 0.28). People tried it most for watching TV (91%), reading mail (74%) and recognising people across the room (53%). Asked which aid they preferred for each task afterwards, at most 2 of 34 picked the headset for any single task. Ease of use, perceived simplicity and imagined daily use all fell significantly between drop-off and collection. Side effects were mostly slight (general discomfort 21 of 34, fatigue 11, headache 10), but two people stopped using it because of them and 9 of 42 reported some double vision at near. The trial was not masked and used self-report; the purchase agreement blocked access to the device's own usage logs. The authors could not say how much of the result belongs to this one device and how much to the device type. (2) What the users said (companion qualitative paper). Four themes came out of interviews with all 34: early delight and imagined uses (theatre, crafts, gardening); performance barriers (image quality, screen size, lag when refocusing between near and far, so it worked for "static" tasks but not when the head moved); practicality barriers; and a wish to help design the next one. On practicality: "By the time you've got the glasses, you've already identified who it is." Set-up time was "particularly off-putting" because the imagined uses were quick spot tasks now done with a simple optical magnifier. The wire and controls made starting the device harder and, for some, clashed with their hearing aids; one participant suggested moving the plug from behind the ear. Others wanted everything in the glasses: "I found it too fussy." (3) Lighter or self-contained headsets. The Eye5 is already far lighter than enclosed headsets (78 g against 498 g for the IrisVision Live 1.0, per the qualitative paper), yet some users still found it heavy, because they compare it with spectacles, not with other headsets. Wireless glasses-style devices are sold: the maker describes the eSight Go as a "lightweight, wireless design" with an "ergonomic neck battery pack". Eyedaptic's page for its newer EYE6 says it weighs "under 3 oz." and has all the features of the EYE5, which the same page lists with a 3-hour battery. Eyedaptic's newest model, the EYE7, lists "real-time voice control for hands-free operation" among its AI assistant's capabilities (the EYE6 page already lists voice control), but the maker's FAQ says all its glasses models "are made to be tethered to the remote-control phone" and the glasses "must always be plugged into the phone for operation"; the same FAQ says prescription lens inserts can be fitted "depending on the model". Its accessory package adds a 5-button handheld remote (zoom, contrast, text modes; the phone must still be connected) and a carry bag for the phone and cable. An older wearable, Enhanced Vision's Jordy (manual dated 2007), did have a place it lived: an optional docking stand. But the stand turned the headset into a desktop video magnifier wired to a TV, and docking meant taking the battery out, so it was a second use, not a way to keep the headset charged and ready to wear. A home-use study of the eSight Go (NCT07149259, Brooks Rehabilitation, US; recruiting since June 2025, about 50 people planned) is registered. A 2026 review co-written by the trial's lead author says newer wEVES have overcome some limitations, but a wearable that looks like ordinary spectacles "still has not been achieved". Our searches found no study testing whether any of them removes the find-charge-start-up delay for a five-second task, against users' own aids in the way this trial did. (4) Earlier studies in mixed, mostly younger populations found quality-of-life gains (a Canadian eSight study of 57 people), and gains concentrated in younger users (a South Korean trial: under 40 only; a Chinese study: smaller gains with age). The authors read these findings as suggesting a greater impact of the current technology among younger users, and a need to study older adults, the group this trial tested, separately.

What would unlock progress

Treat "time to a usable image" and "bother" as design targets, as hard as magnification and contrast. The users' own priorities were a single self-contained spectacle-style unit, well-defined tactile controls and minimal start-up time. The adjacent lesson is the users' existing kit: a hand magnifier is always on, needs no charging and works in a second, which is why it keeps winning spot tasks. A wearable that is "always ready" (a standby state, a one-press wake, a place it lives that is also where it charges), that works over the user's own distance prescription, and that does not compete with hearing aids for the space behind the ear would remove most of the practicality barriers users named. The authors expect the performance problems (image quality, lag) may be resolved by better screens and cameras, but they found the practicality barriers are separate and limited use even when the image was good.

How we’d know it’s being solved

(a) In a home trial like this one, a wearable becomes the preferred aid for at least some tasks for a meaningful share of older users with AMD, compared against their own up-to-date aids (here: at most 2 of 34 for any task). (b) Use is sustained to the end of a 12-week trial rather than falling, ideally from device logs, which this trial could not obtain. (c) Ease-of-use and willingness-to-pay ratings hold or rise between drop-off and collection instead of falling (here 25 → 8 of 34 willing to buy). (d) A measured "need to image" time for spot tasks (picking it up to reading a label or recognising a face) close to that of a hand magnifier. (e) Change in vision-related quality of life, which did not move here.

Where to start

1. Facility-free door (make a thing): the headset itself is not the team's object; the bother around it is. The users' practical reasons were: too long to find, charge, switch on and set up for a quick look; a wire to a separate controller; a clash with hearing aids behind the ear. So build a non-electronic stand-in with the tested device's weight (78 g, using a spectacle frame and clip-on weights) and a dummy cable, and design how it is carried, put on, parked and woken between tasks: (i) a "ready" place it lives, a stand, case or neck holder from which it lifts straight onto the face in one movement, with a dummy charging contact showing where it would charge while parked, so it is never found flat; (ii) a large, well-defined tactile wake control placed where a hand lands while putting it on (the users asked for tactile controls and minimal start-up), mocked up as a button with no electronics behind it; and (iii) a cable route and connector position that clears behind-the-ear hearing aids and spectacles, which the users asked for. Check what is sold first: the page found wireless headsets (the eSight Go, with a neck battery pack and travel case; its maker's page also lists "Tactile control buttons", so (ii) starts from those), makers' lanyards, neck bags, a power hub and a 5-button handheld remote, and an old docking stand that turned a headset into a desk magnifier (Jordy), but no charge-and-wear dock for a wearable in product, retailer or patent searches. Standby and wake already exist on two products: the eSight Go manual describes a sleep mode entered and left by a tap on the power button, and IrisVision's Vista guide an automatic sleep after five minutes and a spoken wake word. Neither maker describes waking when the headset is lifted or put on, so (ii) is about where the hand finds the control, not about adding a standby. The "ready place" idea is already sold for illuminated hand magnifiers: Schweizer's ERGO-Lux i mobil sits on an inductive charging pad, so "the magnifier has its fixed place and is always ready for use". Start from that pad, and solve what it does not: a head-worn unit with a cable or controller that lifts off the stand onto the face in one movement. Build only what is not already sold. Judge the result against the delay those products leave. Measure, with a stopwatch and student volunteers, the seconds from "I need to see this" to the stand-in on the face with a hand on the wake control, against a hand magnifier from the same drawer. No partner or data is needed; any campus makerspace can print the parts. 2. User door: the main users are older adults with macular degeneration; people with other kinds of low vision can test handling too. Reach them through a local low vision service or sight-loss support group, a senior centre, a low vision clinic where the campus has an optometry school, or, for students and staff with low vision, the campus disability office. Some in the trial said the wire clashed with their hearing aids, so the cable-and-ear test matters to them. In short, supervised, seated sessions (no walking while wearing a headset, which manufacturers advise against), compare the team's dock, wake control and cable route with the stand-in alone, on time to ready and comfort over 20 minutes, and ask which spot tasks they would use it for. Testing with people, especially older adults with sight loss, needs the campus's ethics review before any session. Where people are reached as patients of a clinic or low vision service, the team designs the session and the clinic decides whether and how it is run. 3. Design the trial: a home trial with a real device is designed, not run: write the protocol, using this trial's VA-VFQ48, its preferred-aid question and device logs (which this trial could not obtain) as outcomes. Relevant skills: industrial and product design, human factors, simple mechanical design.

Genes

Related problems

Stuck the same way, in other fields.

field: the built worldcracks you cannot rule outNo method can reliably confirm or rule out hidden cracks inside an earthen dam, so owners pay for repairs to defects they cannot findtested in the wrong worldsource: secondaryfield: the built worldretrofit panels above the fifth floorPrefabricated deep-retrofit facade panels stop at five stories — no established attachment or stacking system exists for the taller buildings U.S. housing needs retrofittedtested in the wrong worldsource: primaryfield: food & the living worldharvested, then lostSmallholder farmers in developing countries lose up to 15% of income to preventable food spoilagetested in the wrong worldsource: secondaryfield: food & the living worldthe pesticide that killed the wrong insectEffective neonicotinoid pest control devastates pollinator populations it was not targetingtested in the wrong worldsource: primary

Sources

  • Miller A, Crossland MD, Macnaughton J, Latham K. "The Usefulness of a Wearable Electronic Vision Enhancement System for People With Age-Related Macular Degeneration: A Randomized Crossover Trial." Translational Vision Science & Technology 2025;14(9):8, doi:10.1167/tvst.14.9.8, accessed 2026-11-17. Link ↗
  • Miller A, Macnaughton J, Crossland MD, Latham K. "'Such a lot of bother': Qualitative results of a home trial of a wearable electronic vision enhancement system for people with age-related macular degeneration." Ophthalmic and Physiological Optics 2025;45(3):699-712, doi:10.1111/opo.13453, accessed 2026-11-17. Link ↗
  • eSight, "eSight Go User Manual" (maker's manual), accessed 2026-11-17. Link ↗
  • IrisVision, "Vista User Guide" (maker's help page), accessed 2026-11-17. Link ↗
  • Vision Aid, EYE5 product page (retailer), accessed 2026-11-17. Link ↗
  • Enhanced Vision, "JORDY: Two Low Vision Systems In One. User Manual" (maker's manual), accessed 2026-11-17. Link ↗
  • A. Schweizer GmbH, "ERGO-Lux i mobil – Inductive LED hand magnifier" (maker's product sheet), accessed 2026-11-17. Link ↗
  • Stalin A, Miller A, van der Aa H, et al. "The Evolving Landscape of Vision Rehabilitation: Current Status and Future Directions." Ophthalmic and Physiological Optics 2026;46(6):1397-1406, doi:10.1007/s44402-026-00088-2 (wearable-headset passage read; Europe PMC PMC13694384), accessed 2026-11-17. Link ↗
  • Brooks Rehabilitation, "Assessing the Impact of eSight Go At-Home Usage in Individuals With Visual Impairment" (ClinicalTrials.gov record NCT07149259), accessed 2026-11-17. Link ↗
  • eSight, "eSight Go" (maker's page), accessed 2026-11-17. Link ↗
  • Eyedaptic, "Revolutionary AR Glasses for Vision Loss: EYE6" (maker's page), accessed 2026-11-17. Link ↗
  • Eyedaptic, "EYE7" (maker's page), accessed 2026-11-17. Link ↗
  • Eyedaptic, "Frequently Asked Questions" (maker's page), accessed 2026-11-17. Link ↗
  • Eyedaptic, "Accessories" (maker's page), accessed 2026-11-17. Link ↗
Revision notes

This brief gets checked against its sources and contains the following revisions. Future revisions get added here.

Worth knowing

  • The evidence is one home trial of one headset with 34 older adults, and the trial could not obtain the devices' usage logs.

Full check

Sources read

  • Miller, Crossland, Macnaughton and Latham, randomised crossover trial of a wearable magnifier (Translational Vision Science & Technology, 2025): full text
  • Miller, Macnaughton, Crossland and Latham, interviews from the same home trial (Ophthalmic and Physiological Optics, 2025): full text
  • Stalin and others, review of vision rehabilitation (Ophthalmic and Physiological Optics, 2026): full text (read for its passage on wearable magnifiers and its author list)
  • ClinicalTrials.gov record NCT07149259: full text
  • Eyedaptic product, FAQ and accessories pages: full text
  • eSight Go product page: full text
  • Enhanced Vision Jordy manual and press release: full text
  • Schweizer magnifier product sheet: full text
  • Vision Aid retail page: full text

What changed

  • Not found in the sources, removed: a description of one company named in the trial's disclosures, which no source gives.
  • Not found in the sources, replaced with what they say: that whether newer devices remove the start-up delay 'has not been tested'; no source says so, and the page now says its searches found no such study; that older people with macular degeneration are where the device type has shown least; the trial says earlier findings suggest a greater impact in younger users and a need to study older adults separately.
  • Stated more strongly than the source: users' reasons were called mostly practical, not optical; the interview paper gives image problems and practical problems as two separate themes without ranking them, and the Problem Statement, the Unlock and the first door now say so; a short demonstration was called a poor guide to use; the trial says it tells less than a home trial about whether the device will be useful.
  • Entry points: the trial-design door no longer reads as if the trial had device logs; it says the trial could not obtain them; the first door now notes that one headset's maker already lists tactile control buttons.

Left open

  • the prevalence figures (given as the trial reports them; their source was not read)
  • the earlier Canadian, South Korean and Chinese studies (read only as the trial paper describes them)
  • that no charge-and-wear dock for a wearable magnifier was found (rests on the page's own searches)

Separate check of specific claims: Two headsets were found to have standby and wake already (a tap of the power button; automatic sleep with a spoken wake word), so the first door now asks only where the hand finds the control; the most expensive model is now marked as discontinued, a safety line leaves clinic sessions to the clinic, and citations for the sources the page uses were added to its source list.

Earlier full check: Four fixes: the trial recruited from a Birmingham service and support groups; claims about the disease growing and treatments slowing it were replaced with the trial's own figures; one model's weight and battery figures belonged to an earlier model; and voice control is not new with the newest model.

Separate check of specific claims: A search for existing products found that the newest headset is still tethered to a phone, an old docking stand turned a headset into a desk magnifier with its battery removed, and a hand magnifier with a charging pad is sold; What's Been Tried and the first door now include these.

Separate check of specific claims: The entry points were split into three doors; the first is mocked up on a weighted dummy with no electronics built, and the second adds kinds of place to reach users and a firmer ethics line.

Earlier full check: The display title changed from 'Better Sight, Back in the Box' to 'It Helped, but the Old Aids Won', because the trial, not the users, collected the devices; 'the first randomised trial' became 'a randomised crossover trial', the trial's positive finding and its money-no-object framing for buying were added, and overstated lines were toned down.